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Abstract: In this systematic review, we assessed the effectiveness of systemic antibiotics as an
adjunctive therapy to mechanical debridement in improving inflammatory systemic biomarkers,
as compared to mechanical debridement alone, among adults with chronic periodontitis. We
searched relevant electronic databases for eligible randomized controlled trials. Two review authors
independently screened, extracted data, and assessed risk of bias. We conducted meta-analysis,
assessed heterogeneity, and assessed certainty of evidence using GRADEPro software. We included
19 studies (n = 1350 participants), representing 18 randomized controlled trials and found very little or
no impact of antibiotics on inflammatory biomarkers. A meta-analysis of eight studies demonstrated
a mean reduction of 0.26 mm in the periodontal pockets at three months (mean difference [MD]
−0.26, 95%CI: −0.36 to −0.17, n = 372 participants, moderate certainty of evidence) in favor of the
antibiotics. However, results from five studies reporting clinical attachment level (mm) yielded little
or no difference at three months (MD −0.16, 95% CI: −0.35 to 0.03, n = 217 participants) between
antibiotic and placebo groups. There is little or no evidence that adjunctive systemic antibiotics
therapy improves inflammatory systemic biomarkers, compared to mechanical debridement alone,
among adults with chronic periodontitis.
Keywords: chronic periodontitis; mechanical debridement; antibiotics; systemic biomarkers
1. Background
According to the World Health Organization (WHO), oral diseases are the most common
non-communicable diseases with severe periodontal disease being the 11th most prevalent disease
worldwide [1]. Periodontal disease is a chronic inflammatory disease of the periodontium and the
most prevalent infectious oral condition [2]. Although the disease can be treated and prevented, it is
the most frequent cause of tooth loss in adults. The signs and symptoms of periodontitis include
persistent halitosis, red or swollen gingiva, tender or bleeding gingiva, painful mastication, loose
teeth, and gingival recession. A new identification and classification system of periodontitis was
developed in 2017 whereby the 1999 classification of chronic periodontitis is incorporated under the
category of periodontitis (previously considered as either chronic or aggressive) [3]. The prevalence of
periodontitis ranges 5–15% in most populations [4]. Globally, periodontal disease had an estimated
prevalence of 750,847,000, incidence of 89,840,000, and 4,898,000 years lived with disability (YLD),
in 2016 [5].
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The diagnosis of periodontal disease is based on clinical measures such as bleeding on probing,
pocket probing depth, and attachment loss, as well as radiological evidence of bone destruction [6].
Periodontal treatment entails the elimination of biofilm and microbial deposits from the root surfaces,
thus reducing the inflammatory host response and tissue destruction [7,8]. Although there are several
treatment approaches for periodontitis, conservative mechanical debridement (scaling and root planing
[SRP]) has been the most common therapy [9]. Depending on the severity of inflammation, mechanical
debridement combined with systemic antibiotic use has been advocated as a treatment possibility.
However, there is currently insufficient scientific evidence to support or refute whether systemic
antibiotics effectively enhances a positive outcome in chronic periodontal disease [10–15].
Therefore, this systematic review assessed the effectiveness of systemic antibiotics as an adjunctive
therapy to mechanical debridement in the improvement of inflammatory systemic biomarkers,
as compared to mechanical debridement alone, among adults with chronic periodontitis, using
evidence from published randomized controlled trials.
2. Methods
This systematic review followed the preferred reporting items for systematic reviews and
meta-analyses (PRISMA) statement for reporting systematic reviews and meta-analyses of studies that
evaluate healthcare interventions [16]. The protocol for study was registered with the International
Prospective Register of Systematic Reviews (PROSPERO), (registration number: RD42017059053).
2.1. Criteria for Considering Studies for This Review
2.1.1. Types of Studies
We included all randomized controlled trials (RCTs), published between January 2000 and October
2019, evaluating systemic antibiotics combined with mechanical debridement versus mechanical
debridement alone or with placebo. Quasi-randomized controlled trials were also eligible, as well as
studies in abstract only, with relevant results. Non-randomized trials and observational studies met
the exclusion criteria.
2.1.2. Types of Participants
We included adults, aged 18 years and older, diagnosed with periodontal disease with or without
co-morbidities such as diabetes mellitus, cardiovascular diseases, chronic obstructive pulmonary
disease, and chronic kidney disease.
2.1.3. Types of Interventions
Experimental
All interventions that included mechanical debridement combined with adjunctive systemic
antibiotics for the treatment of chronic periodontitis.
Control
The trials compared antibiotics versus placebo or no antibiotic, with mechanical debridement in
either arm of the intervention.
2.1.4. Types of Outcome Measures
Primary Outcomes
The primary outcomes were changes in blood levels of inflammatory biomarkers such as Matrix
Metalloproteinases (MMPs), Tissue Inhibitors of MMPs (TIMPs), Cytokines/Interleukins (IL-1β, IL-6
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and IL-8), C-Reactive Protein (CRP), Glycosylated Hemoglobin (HbA1c), and Tumor Necrosis Factor
alpha (TNF-α).
Secondary Outcomes
The secondary outcomes were periodontal parameters including pocket depth and clinical
attachment level (CAL).
2.2. Search Methods for Identification of Studies
We adopted the following search terms and strategy: "anti-bacterial agents” [medical subject
headings (MeSH)] OR "anti-infective" OR “systemic antibiotics” OR “antibiotic OR "antibiotic therapy”)
AND (periodontitis OR “chronic periodontitis” OR “periodontal diseases” [MeSH] OR “periodontitis”
[MeSH].
We used the search strategy to identify relevant trials in MEDLINE database, and adapted the
same strategy for other relevant electronic databases that we searched. We considered relevant RCTs
published from January 2000 to October 2019 for inclusion. We did not apply any language restrictions.
2.2.1. Electronic Searches
We searched the following databases to identify relevant trials: Cochrane Oral Health Group’s
Trials Register, CENTRAL—Cochrane Register of Controlled Trials (of the Cochrane Library—current
issue), MEDLINE (1966 to present), EMBASE (1982 to present), CINAHL (1990 -present), and Google
scholar (1990–present).
2.2.2. Ongoing Trials Databases
We searched the following on-going trials registers (31 October 2019) to identify relevant trials:
The meta-Register of Controlled Trials (www.controlled-trials.com), the US National Institutes of
Health On-going Trials Register (www.clinicaltrials.gov), the World Health Organization International
Clinical Trials Registry platform (www.who.int/trialsearch).
2.2.3. Grey Literature
We also searched the reference lists of included trials (31 October 2019) for relevant trials. We also
emailed the authors of included trials and experts in the field of oral health care to identify any
additional published or unpublished trials (31 October 2019). We searched the ProQuest database,
Stellenbosch University database, and Google scholar (31 October 2019) and hand searched for trials
not indexed in databases.
2.3. Data Collection and Analysis
2.3.1. Selection of Studies
Two review authors (SM and ET) independently screened the titles and abstracts of the search
output to select potentially eligible trials using pre-specified eligibility criteria. After removing
duplicates and ineligible trials, we retrieved the full-text articles of potentially relevant trials. Any
disagreements were resolved through discussion or the third and fourth review authors (UMEC and
AM) would add their input to enable a consensus.
2.3.2. Data Extraction and Management
Two review authors (SM and ET) also independently extracted data from each included trial using
a pre-piloted data extraction form specifically designed for this review. The extracted data included
study characteristics (authors, year, country and setting, and funding) and participant characteristics
(study population, age, gender, periodontal disease diagnosis and severity, number of participants
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recruited and number of participants completing the trial, withdrawals and the reasons thereof, and
overall sample size). Three review authors (SM, ET, and AM) extracted data for primary and secondary
outcomes. For continuous outcomes that could be assumed normally distributed, such as pocket depth
(in mm), we extracted the mean and standard deviation. For other continuous outcomes containing
outliers, such as IL-1β, IL-6, IL-8, CRP, and CAL, we extracted the medians and their corresponding
inter-quartile ranges (IQR). Otherwise, we extracted any other relevant data such as median ratios,
95% confidence intervals (CI), and p-values, as reported by study authors.
2.3.3. Assessment of Risk of Bias of Included Studies
Two review authors (SM and ET) independently assessed the risk of bias assessment for each of
the included studies, in accordance with the guidelines in the Cochrane Handbook for Systematic
Reviews of Interventions and levels of attrition were noted [17]. Each domain of risk of bias (generation
of allocation sequence, allocation concealment, blinding of participants and personnel, blinding of
outcome assessors, incomplete outcome data, selective outcome reporting, and other bias) were
judged as either low risk, high risk, or unclear. Disagreements were resolved by discussion or by
consulting AM.
2.3.4. Measures of Treatment Effect
We calculated the mean difference (MD), with its corresponding 95%CI, for continuous data with
the same scale (for instance, pocket depth (mm)). Where continuous data could not be assumed to be
normally distributed and study authors reported medians and ranges (for instance, CRP), we reported
the median (IQR) together with any reported p-values for group comparisons, as given by study
authors. For binary data, the reported odds ratios (OR) and corresponding 95% CI’s and p-values
were reported.
2.3.5. Unit of Analysis Issues
We performed analyses at the participant level to avoid unit of analysis errors. We did not
include any crossover or cluster-randomized trials. For trials that had multiple intervention groups, we
combined relevant groups to create single pairwise comparison. For one three-arm trial, we selected
one pair of interventions and excluded one arm that was not relevant for this review.
2.3.6. Dealing with Missing Data
We contacted study authors to request information regarding missing data on either outcomes or
risk of bias; however, we did not receive any responses. For each outcome in each trial, the denominator
was the number of randomized subjects excluding any participants whose outcomes were missing. We
therefore used the available case analysis and did not perform any data imputation.
2.3.7. Data Synthesis
We performed inverse variance random effects meta-analysis using RevMan statistical software
version 5.3 (The Nordic Cochrane Centre, Copenhagen, Denmark) for some continuous secondary
outcomes such as pocket depth (mm). To assess the extent and significance of heterogeneity, we used
the I2 test statistic and the Chi2 test (p < 0.1 indicated statistical significance). Due to insufficient
data, we could not pool results of many outcomes in a meta-analysis, and we reported the results
separately for each study. We used GRADE Profiler (GRADEpro, version 3.6) software to assess the
quality of evidence on the four main outcomes (HbA1c, MMP-8, CRP, and probing depth at 3 months)
by rating the quality of evidence as either high, moderate, low, and very low certainty of evidence
and summarized the results in the Summary of Findings table. Grading of the evidence considers
factors such as study limitation (risk of bias), imprecision, inconsistency, indirectness of results, and
publication bias [18].
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3. Results
3.1. Results of the Search
The search yielded a total of 1730 titles and abstracts (1717 from electronic searches and 13 from
hand searches). We excluded 1128 duplicates and remained with 602 records. We screened these
602 titles and abstracts and retained 58 records for further assessment. We also identified two additional
articles from an updated search. We then retrieved full-text articles of these 60 studies and re-screened
them for eligibility, from which we excluded 41 studies with reasons, thus retaining with 19 studies that
we included in this review [13,15,19–35]. We report on 18 randomized controlled trials considering that
two studies [26,31] were from the same trial. One trial [35] was published in French and we obtained






Figure 1. Search results for studies on the effect of antibiotics in addition to mechanical debridement among 
adults with chronic periodontitis 
3.2. Settings, Participants, and Interventions 
The characteristics of included studies are summarized in Table 1. 
 
Figure 1. Search results for studies on the effect of antibiotics in addition to mechanical debridement
among adults with chronic periodontitis
3.2. Settings, Participants, and Interventions
The c aracteristics of i ed studies are summarized in Table 1.
Int. J. Environ. Res. Public Health 2020, 17, 5601 6 of 19
Table 1. Characteristics of included studies on the effect of antibiotics in addition to mechanical debridement among adults with chronic periodontitis.
Study ID Country and Setting Patients Trial Duration Intervention Control
Almaghlouth 2014 [19] School of Dental Medicine of theUniversity of Geneva, Switzerland
40 patients with moderate-to-advanced
periodontitis, aged 25–70 years 3 months
500 mg Metronidazole+ 375 mg
Amoxicillin three times a day for 7 days No placebo
Botero 2013 [20] San Vicente de Paul Hospital Medellin,Colombia, South America
105 adults diagnosed with moderate
periodontitis and diabetes 18 months
Azithromycin tablet 500 mg daily for
3 days (Group 1: Az+Scaling, Group 2:
Az+Prophylaxis)
Placebo
Cionca 2009 [21] School of Dental Medicine, University ofGeneva, Switzerland
51 adult patients with moderate to
advanced periodontitis, between ages of
25–70 years
1 year 500 mg Metronidazole & 375 mgAmoxicillin t.i.d × 7 days
Placebo capsules of 500 mg
and 375 mg t.i.d. × 7 days
Engebretson 2011 [22]
Naomi Berrie Centre and Department of
Periodontics, Columbia University
Medical Centre, USA
45 Type 2 diabetes patients with chronic
periodontitis, aged 50–56 years. 3 months
Group 1: 20 mg Sub-antimicrobial dose
doxycycline (SDD) b.i.d × 3 months
Group 2: 100 mg ADD daily × 3 months
Placebo daily × 3 months
Gaikwad 2013 [23] Department of Periodontics, TatyasahebKore Dental College, India
50 diabetes patients with chronic
generalised periodontitis aged
30–70 years.
3 months 100 mg Doxycycline once daily for15 days No placebo
Gilowski 2012 [24] Medical University of Silesia, Katowice,Poland
34 type 2 diabetes patients with chronic
periodontitis, aged 36–68 years 3 months
20 mg doxycycline hydrochloride three
times a day for 3 months No placebo
Golub 2008 [26] and
Payne 2011 [31]
University of Nebraska Medical Centre
College of Dentistry and the School of
Dental Medicine at Stonybrook University,
Stoney Brook, USA
128 Osteopenic post-menopausal women
with moderate to advanced periodontitis
between the ages of 45–70 years
2 years
20 mg Sub-antimicrobial dose
doxycycline (SDD) × 3 times a day for
2 years
20 mg Placebo × 3 times a day
for 2 years
Golub 2001 [25]
Department of Oral Biology & Pathology,
School of Dental Medicine, State
University of New York at Stony Brook,
USA
174 adult patients with chronic
periodontitis aged 18–75 years 9 months
Group 1–4 Doxycycline 20 mg ×
12 weeks (in different combinations) Placebo × 12 weeks
Han 2012 [27] Department of Periodontology, School ofDentistry, Ege University, Izmir, Turkey
36 patients with severe generalised
chronic periodontitis in the age range of
35–54 years
6 months 500 mg Azithromycin once daily × 3 days 500 mg Placebo once daily for3 days
Jones 2007 [28]
All four departments of Veterans
Administration facilities at Greater Boston,
USA
165 diabetes patients with periodontitis,
mean (SD) age of 59.1(11) years 4 months 100 mg doxycycline daily for 14 days Usual care with no placebo
Lopez 2012 [29] Dr. Eloisa Diaz Dental Center, San JoséHospital, Santiago, Chile
165 patients with Metabolic Syndrome
(MetS) having periodontitis, between the
ages of 35–65 years
1 year 250 mg Metronidazole t.i.d AND 500 mgAmoxicillin t.i.d for 7 days
250 mg placebo t.i.d AND
500 mg placebo t.i.d for 7 days
Miranda 2014 [30]
Department of Periodontology, Dental
Research Division, Guarulhos University,
Sao Paulo, Brazil
58 Type 2 diabetes patients with
generalized chronic periodontitis, aged
35 years or more.
1 year 400 mg Metronidazole+ 500 mgAmoxycillin three times a day for 14 days Placebo
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Table 1. Cont.
Study ID Country and Setting Patients Trial Duration Intervention Control
O’Connell 2008 [15]
Department of Oral Surgery &
Periodontology, University of São Paulo
Ribeiro-Preto, Brazil
30 Type 2 diabetes patients with
periodontitis, aged 46–70 years 3 months
100 mg Doxycycline once daily for
2 weeks after an initial dose of 200 mg
Placebo once daily for 2 weeks
after initial dose of placebo
Rooney 2002 [32] Department of Periodontology at BristolDental School and Hospital, USA
66 patients with advanced chronic
periodontal disease between the ages of
20–45 years
6 months
Group 1 (AM): 250 mg Amoxycillin
(capsule) and 200 mg metronidazole
(tablet). Group 2 (PM): 200 mg
metronidazole (tablet) and placebo
(lactose capsules). Group 3 (AP): 250 mg
Amoxycillin (capsule) and placebo
(calcium lactate tablets).
Placebo (lactose capsules) and
placebo (calcium lactate
tablets).
Saleh 2016 [33] Oral Health Centre, University of WesternAustralia, Australia
37 adults with generalized moderate to
advanced chronic periodontitis, age of
30 years and older
3 months
Group 1: 500 mg Amoxicillin and 200 mg
Metronidazole administered every 8 h
for 7 days
Group 2: 500 mg Azithromycin
administered every 8 h for 7 days
Placebo capsules were
administered every 8 h for
7 days
Soto 2016 [35]
Two university clinics in the city of Cali
(Colombia), and the Universidad del Valle
(university of Valle)
81 patients with moderate to severe
chronic periodontitis, aged between 25
and 70 years
12 weeks 500 mg Azithromycin per day, for 5 days Placebo
Tuter 2007 [13] Department of periodontology of GaziUniversity, Ankara, Turkey
36 patients with both chronic
periodontitis and coronary artery disease
(CAD), and age < 70 years
6 weeks
20 mg Sub-antimicrobial dose
doxycycline (SDD) three times daily for
6 weeks
20 mg Placebo, three times
daily for 6 weeks
Winkel 2001 [34]
Clinic for Periodontology Amsterdam and
the Clinic for Periodontology Utrecht,
The Netherlands
49 patients with generalised severe
periodontitis, mean age of at least
40 years
6 months
375 mg Amoxicillin in combination with
250 mg metronidazole to be taken every
8 h for next 7 days was given.
Similar placebos every 8 h for
next 7 days was given
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The trials were conducted in academic hospitals mainly in developed countries: Six from the
USA [22,25,26,28,31,32]; five from South America (Colombia [20,35], Brazil [15,30] and Chile [29]); five
from Europe (Switzerland [19,21], Poland [24], Turkey [13,27]); and one from Australia [33]. Only
one study was from a developing country, India [23]. None of the included studies were conducted
in Africa.
In total, 1350 participants (18 trials) were included in the analysis for this review. The
age of the participants ranged from 18 to 75 years old. Participants were all diagnosed with
moderate-to-advanced chronic periodontitis with or without comorbidities. Eight trials included
participants with no comorbidities [19,21,25,27,32–35]. Seven trials [15,20,22–24,28,30] included
participants with hyperglycemia (diabetes), one trial [13] recruited participants with coronary artery
disease (CAD), another trial [29] included participants with metabolic syndrome (MetS), and the last
trial reported by two studies [26,31] assessed osteopenic postmenopausal women (Table 1).
All included trials assessed the effect of antibiotics compared with placebo or no antibiotic with
mechanical debridement in both groups. The duration of the trials ranged from 6 weeks to 18 months.
The intervention groups had broad spectrum antibiotics as an adjunct to the non-surgical therapies
received. Combination of interventions varied across included trials. Four trials [20,27,33,35] evaluated
the effect of 500 mg azithromycin in the treatment group compared to placebo. Seven trials examined
the effects of doxycycline against either a placebo [15,22,25,26] or no placebo [23,24,28]. Seven trials
investigated the effect of a combination of metronidazole and amoxicillin, albeit utilizing different
dosages, versus either placebo [21,29,30,32–34] or no placebo [19] (Table 1).
Some of the trials were multi-arm. One trial [20] randomized patients into three treatment
groups: Non-surgical therapy plus azithromycin, non-surgical therapy plus placebo, and supragingival
prophylaxis plus azithromycin; we analyzed the first two groups and excluded the third group since it
had no SRP. The second trial [22] was also a three-arm trial with conventional subgingival debridement
combined with either sub-antimicrobial-dose doxycycline (SDD), anti-microbial dose doxycycline
(ADD), or placebo. The third trial [25] consisted of four groups of various 20 mg doxycycline
prescriptions versus placebo. The fourth trial [32] was a four-arm trial where all patients received
quadrant SRP and were then prescribed 250 mg amoxicillin and 200 mg metronidazole (AP) or lactate
and metronidazole (PM) or amoxicillin and calcium lactate (AP) or lactate and calcium lactate (PP).
The fifth trial [33] is a three-arm trial, the first group received 200 mg metronidazole plus 500 mg
amoxicillin, the second group were given 500 mg azithromycin, and the control group received placebo.
For the analysis of these multi-arm trials, we combined the antibiotic groups to create single pairwise
comparison with the placebo.
3.3. Risk of Bias of Included Studies
The risk of bias assessments for each included study are summarized in Figure 2. We judged
12 studies at low risk of random sequence generation (selection bias) because they reported using
computer generated random numbers [19–22,25–31,33]. The remaining seven studies were unclear on
how they generated the random allocation sequence [13,15,23,24,32,34,35].
We judged six studies at low risk of allocation concealment (selection bias) because four reported
use of opaque, sealed, and coded envelopes to conceal the assignment [19,20,29,30] and two described
the assignment as being concealed and allocation visually indistinguishable [22,27]. Thirteen studies
were unclear on how they concealed allocation [15,21,23–26,28,31–35].
We judged 13 studies at low risk of performance bias because they reported adequate masking of
participants and personnel (dentist, dental technician, and dental assistant) [13,19–21,24–27,30–33,35].
Information provided by the authors of five studies was unclear [15,22,23,29,34]. We judged one
study at high risk of performance bias because the dentist, dental technician, dental assistant, and
participants, were not masked [28].
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Figure 2. Risk of bias graph for studies assessing mechanical debridement with antibiotics in the
treatment of periodontitis.
We judged eight studies at low risk of detection bias because they described an adequate method
of blinding outcome assessors [20,26–31,34]. The remaining 11 studies were unclear of detection
bias [13,15,19,21–25,32,33,35].
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We judged 17 studies at low risk of attrition bias since they had low attrition [13,15,19–24,26,27,29–35].
We judged two studies at high risk of attrition bias because they had more than 15% of participants not
completing the study and did not impute missing data [25,28].
We judged all the 19 included studies at low risk of reporting bias because they reported all
expected outcomes as pre-specified in their methods.
We did not identify any other risk of bias in any of the 19 included studies.
3.4. Effects of Interventions
The GRADE Summary of Findings Table summarizes the results for four outcomes (Pocket depth
(mm) at three months, HbA1c, MMP-8, and CRP levels) (Table 2). The detailed results for each of the
primary and secondary outcomes follows.
Table 2. GRADE Summary of Findings Table for studies assessing mechanical debridement with
antibiotics in the treatment of periodontitis.
Summary of Findings Table:
Antibiotic compared to placebo in the treatment of chronic periodontitis
Patient or population: Adult patients diagnosed with chronic periodontitis
Setting: Academic dentistry hospitals or clinics in developed countries
Intervention and Comparison: Antibiotic compared placebo or no antibiotic
Outcomes




























Meta-analysis of eight studies with
372 participants show an antibiotic
effect of reducing pocket depth by
0.26 mm compared to the placebo
(moderate certainty of evidence).
One other study found reduction in
favour of the antibiotics, however
results were presented as medians
and ranges. Three other studies
found little or no difference between








Six studies with 382 participants
found little or no difference in the
effect of antibiotics on haemoglobin
levels compared to the placebo
group. One study with 105
participants was unclear on the
differences between the antibiotic
and placebo groups.




Three small studies with 106
participants found little or no impact
of antibiotic therapy on MMP-8
levels. One study with 128
participants found a 60% reduction
in favour of antibiotics during a
2-year period.
C-Reactive






Three studies with 282 participants
found little or no difference in CRP
levels between the antibiotic and
placebo groups. One study with 40
participants was unclear on the
inter-group differences. One study
with 182 participants found a small
antibiotic effect of 18% decrease.
* The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of
the intervention (and its 95% CI). CI: Confidence interval; MD: Mean difference
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a
possibility that it is substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
a. Downgraded for indirectness as most studies were done in developed countries and results may not be
generalizable globally; b. One study (Jones 2007) had high risk of performance and attrition bias; c. Indirectness:
Outcomes were reported in different forms by studies and could not be pooled in a meta-analysis. In addition most
studies were done in developed countries and results may not be generalizable globally. d. Three studies had small
sample sizes of below 40.
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3.5. Primary Outcomes
3.5.1. Cytokines/Interleukins
Three studies reported on IL-1β [15,19,26]. One study [19] assessed 40 participants (19 receiving
antibiotic and remaining 21 placebo) and observed peak values of IL-1β in four patients at baseline
(values ranging from 4.8 to 226.5 pg/mL), but no peak values were detected in any of the patients
after three months. Another study [26] assessed gingival crevicular fluid (GCF) IL-1β levels in 128
postmenopausal women (64 in subantimicrobial-dose doxycycline (SDD) antibiotic group and 64
in placebo group) with chronic periodontitis, however there was no significant difference in the
median GCF IL-1β levels between the two treatment groups after one-year or two-years’ time-point, as
reported by the study authors. The third study [15] evaluated 30 participants with type 2 diabetes
and periodontitis (15 intervention and 15 placebo) but found no reduction in the concentration of
IL-1β between baseline and three months (it remained at mean (standard error [SE]) of 0.3(0.3) pg/mL);
however, the study authors did not give separate results for the intervention and placebo groups.
Three studies reported IL-6 [15,19,31]. One study [19] reported that a participant had a peak
value of IL-6 of 216.3 pg/mL at baseline out of 40 periodontally diseased participants but there were no
participants with peaked values after three months. Meanwhile, it is not clear whether the participants
received antibiotic or placebo. The second study [15] reported a decrease in IL-6 in the mean (SE) of
2.1(0.3) at baseline to 1.1 (0.2) at 3 months (p = 0.005) for 30 participants with type 2 diabetes and
periodontitis; however, the authors did not report separate values for the intervention and control
groups except to say that there were no significant differences observed between treatment groups. The
third study [31] found no significant difference in IL-6 level between the antibiotic group (SDD) and
placebo group in 128 post-menopausal women with chronic periodontitis after two years (40% SDD
versus 46% placebo; odds ratio [OR] 0.72, 95%CI: 0.30 to 1.69, p = 0.4).
One study [19] reported a peak value in IL-8 of 38.3 pg/mL at baseline for one participant, which
rose to 39.6 after three months; but it is not clear whether the participant received antibiotic or placebo.
Another study [15] reported a slight increase in IL-8 from mean (SE) of 9.0 (1.1) at baseline to 10.6
(2.5) at three months (p = 0.621) for 30 participants with type 2 diabetes and periodontitis; however,
the study did not give separate values for intervention and placebo groups except to say there were no
significant differences observed between treatment groups.
3.5.2. C-Reactive Protein (CRP)
Five studies reported on CRP [13,19,29,31,35]. From our GRADE assessments, we found little
or no antibiotic effect on CRP levels (low certainty of evidence after downgrading two levels for
indirectness). In one study [19], peak values of CRP were observed in four participants at baseline
(values ranging from 13.4 to 52.6 µg/mL) and in three participants at three months (14.1 to 33.4 µg/mL);
however, the study authors gave no indication of how many of the participants with these peak values
received antibiotics. Another study [29] assessed CRP levels in participants with metabolic syndrome
where 82 participants received amoxicillin and metronidazole while 83 participants received placebo.
Although the mean CRP levels decreased significantly at 9 and 12 months, there were no significant
differences between the two treatment groups at three months. In a third study [31], the SDD antibiotic
intervention significantly reduced median hs-CRP by 18% over a period of two years compared to the
placebo and the ratio of medians of SDD versus placebo (0.82, 95%CI: 0.70 to 0.97, p = 0.02). A fourth
study [13] also assessed the effect of the SDD antibiotic on high-sensitivity CRP (hs-CRP) compared to
placebo; however, although there were significant improvements between baseline and six weeks in
both groups, there was no significant difference between groups at six weeks (p = 0.628). The fifth
study [35] reported hs-CRP at baseline and 12 weeks and found that treatment with azithromycin
antibiotic decreased the hs-CRP from 4.33 mg/L to 2.99 mg/L while the placebo treatment increased
from 4.59 mg/L to 5.61 mg/L. Although they did not compare these intra-group changes, they found no
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significant differences between groups at 12 weeks (p = 0.4630); we could not calculate the 95%CI for
mean difference since standard deviations were not reported.
3.5.3. MMP-8
Four studies reported MMP-8 [13,24,26,27]. From our GRADE assessments, we found little or
no impact of antibiotic therapy on MMP-8 levels (very low certainty of evidence after downgrading
one level for imprecision due to low sample size and two levels for indirectness). One study [24]
randomized 34 participants (17 receiving SDD and 17 receiving placebo) with chronic periodontitis
and type 2 diabetes; although MMP-8 decreased significantly between baseline and three months
among the SDD group while an increase was observed in the placebo group, there was no significant
difference between the two groups according to the study authors. In the second study [26], the SDD
significantly reduced the odds of increased MMP-8 levels by 60% compared to placebo during the
two-year period of study (OR 0.40, 95%CI: 0.21 to 0.77, p = 0.006) among the 128 postmenopausal
women with periodontitis (64 in each group). In the third study [27], 36 participants with generalized
chronic periodontitis (18 receiving azithromycin and 18 receiving placebo) showed no significant
differences in GCF MMP-8 concentration between the two treatment groups from baseline to six
months. The fourth study [13] demonstrated no significant differences in MMP-8 between the SDD
and placebo group among the 36 participants with chronic periodontitis at pre- and post- six-week
time points, according to study authors.
3.5.4. TIMP-1
One study [31] reported TIMP-1 and found no significant difference between the antibiotic group
(SDD) and placebo group: TIMP-1 among the 128 postmenopausal women with chronic periodontitis
after two years; ratio of medians of SDD versus placebo (0.96, 95%CI: 0.78 to 1.18, p = 0.7), according to
study authors.
3.5.5. HbA1c
Seven studies reported HbA1c levels [15,20,22–24,28,30]. From our GRADE assessments, we
found little or no antibiotic effect on HbA1c levels (very low certainty of evidence after downgrading
one level for high risk of bias and two levels for indirectness). One study [23] found no significant
difference in HbA1c levels (%) at four months of treatment between the SDD and placebo groups among
the 50 participants with type 2 diabetes and chronic generalized periodontitis (Mean (SD) 7.00 (0.76)
SDD versus 7.11 (0.99) Placebo; p = 0.710); however, the different sample sizes in each treatment group
at four months were not given. The second study [24] also found no significant difference in HbA1c (%)
at three months after treatment with SDD compared to placebo among 34 patients with type 2 diabetes
and chronic periodontitis (Median (interquartile range (IQR)) 6.3 (5.5 to 7.3) SDD versus 6.7 (6.3 to 7.7)
Placebo; p = 0.8). The third study [28] evaluated the effect of SDD versus placebo after four months of
treatment among 165 veterans (83 receiving SDD antibiotic and 82 placebo) with periodontitis and
poorly controlled diabetes; there was no significant difference in the percent achieving either HbA1c
decreases of either > 0.5 or > 1.0 (55% versus 52% (p = 0.38) or 41% versus 34% (p = 0.31), respectively).
In the fourth study [20], the antibiotic group had a reduction of 0.8% versus 0.3% in the placebo group
at nine months; however, no comparison p-value was calculated between the two treatment groups.
In the fifth study [22], the mean HbA1c after three months decreased by 0.9% (7.2% to 6.3%) in the
SDD group, increased slightly by 0.3% (7.5% to 7.8%) in the ADD group, but remained the same at
8.5% in the placebo group; there were no significant differences between the antibiotic groups and the
placebo, according to the study authors. The sixth study [30] assessed metronidazole plus amoxycillin
versus placebo among 58 (29 per group) participants with type 2 diabetes and periodontitis but found
no significant difference in HbA1c levels (%) between the two treatment groups at baseline, three
months, six months, and after one year of treatment (p = 0.35, 0.55, 0.33, and 0.62, respectively). The
seventh study [15] found no significant difference in HbA1c (%) improvement between the SDD group
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(1.5%) and placebo group (0.9%) after three months among 30 participants with periodontitis and type
2 diabetes.
3.6. Secondary Outcomes
3.6.1. Probing Depth (PD)
(a) PD (mm)
Eight trials [15,19–21,23,30,33,34] measured PD (mm) at three months and a random effects
meta-analysis of their results yielded a statistically significant antibiotic effect of reducing PD by
0.26 mm (mean difference [MD] −0.26, 95% confidence interval [CI]: −0.36 to −0.17, n = 372 participants,
8 trials, Figure 3) and there was no significant heterogeneity between trials (Chi2 = 7.40, degrees of
freedom [df] = 7, p = 0.39, I2 = 5%). A funnel plot was constructed and it showed no evidence of
publication bias (Figure 4). From our GRADE assessments, this was moderate certainty of evidence after
downgrading one level for indirectness since the studies were done mainly in developed countries only.
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(mm) after six weeks of treatment in favor of the antibiotic group compared to placebo (Median (IQR) of 
3.45 (3.24 to 3.69) mm SDD versus 3.78 (3.52 to 4.2) mm Placebo, p = 0.034, n = 36 participants (18 per group)). 
A fourth trial [30] assessed the antibiotic effect at six months and one year but found no significant 
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One trial [24] also assessed PD (mm) at three months but there were no significant differences
between treatment groups; the results are only reported in a figure (box and whisker plot) from
which values for analysis cannot be accurately extracted. A second trial [27] measured PD reduction
(in mm) from baseline to three months and found no significant difference between antibiotic and
placebo groups (MD 0.25, 95% CI -0.05 to 0.55, n = 28 participants). A third trial [13] found statistically
significant improvements in PD (mm) after six weeks of treatment in favor of the antibiotic group
compared to placebo (Median (IQR) of 3.45 (3.24 to 3.69) mm SDD versus 3.78 (3.52 to 4.2) mm Placebo,
p = 0.034, n = 36 participants (18 per group)). A fourth trial [30] assessed the antibiotic effect at six
months and one year but found no significant difference between groups (data not reported). A fifth
trial [32] reported the mean percent of sites with low (0–3mm) and high (>=6mm) pocket depth in the
four treatment groups at baseline, one, three, and six months. Since the study authors did not report
the pocket depth (in mm), their results are not reported here.
3.6.2. Clinical Attachment Level (CAL)
Nine trials reported CAL [13,15,21,23,24,27,30,33,34]. Five trials [15,23,30,33,34] measured CAL
(mm) at three months and a random effects meta-analysis of their results showed no significant
difference in CAL(mm) (MD −0.16, 95% CI: −0.35 to 0.03, n = 217 participants, 5 trials, Figure 5) and
there was no significant heterogeneity between trials (Chi2 = 1.69, df = 4, p = 0.79, I2 = 0%). One
trial [23] also measured CAL (mm) at four months and found a significant reduction in favor of the
antibiotic group (MD −0.30, 95%CI: −0.55 to −0.05, 50 participants). However, another trial [30] did
not find significant difference between treatment groups at both month 6 (MD −0.30, 95%CI: −0.77 to
0.17, 56 participants) and month 12 (MD −0.40, 95%CI: −0.87 to 0.07, 56 participants, Figure 5).
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6 (MD 0.00, 95%CI: −0.19 to 0.20, 75 participants, 2 studies); there was no significant heterogeneity
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4. Discussion
We assessed the effectiveness of syst mic antibiotics as an adjunctive therapy to mechanical
debridement in the changes of inflammatory systemic biomarkers as well as clinical parameters among
adult patients with chronic periodontitis. We included 18 randomized controlled trials consisting of
1350 adult participants in this systematic review and we found very little impact of antibiotics on
changes in blood levels of infla matory biomarkers such as MMPs, TiMPs, Cytokines/Interleukins
(IL-1β, IL-6, and IL-8), CRP, HbA1c, and clinical attachment level. However, a meta-analysis of
eight studies demonstrated a mean reduction of 0.26 mm in the periodontal pockets at three months
(moderate certainty of evidence) in favor of the antibiotics. In meta-analyses, we did not detect
substantial heterogeneity between studies and the studies generally had either unclear or low risk
of bias. The majority of the studies ere conducted in developed countries, mainly in Europe and
the USA.
To our knowledge, this is the first systematic review to determine the effects of adjunctive
antibiotics on systemic biomarkers. Several systematic reviews have assessed the effects of adjunctive
antibiotics among patients with periodontitis; however, they assessed clinical outcomes only. From the
two most recently published systematic reviews [36,37], the first [36] assessed the effect of adjunctive
systemic antimicrobials on clinical outcomes of periodontitis in randomized controlled trials with
follow-up of at least six months; they found that systemic antibiotic therapy with metronidazole
and amoxycillin significantly improved probing pocket depth as well as clinical attachment level.
The other systematic review [37] assessed adjunctive antibiotics in patients with untreated chronic
periodontitis and also found significant effects of systemic antibiotics on pocket depth reduction at 3, 6,
and 12 months, as well as on clinical attachment level gain after three months of treatment. This is in
agreement with our findings of a statistically significant reduction in pocket depth at three months;
however, our results did not find significant effects in clinical attachment level. The difference in our
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results is probably because we excluded studies before the year 2000 and did not separate analyses for
different types of antibiotics as done in the other two systematic reviews.
In this systematic review, we included adult participants aged 18 to 75 years with moderate
to advanced chronic periodontitis with or without comorbidities mainly from developed countries.
Only one study was from India and none were from the African continent. This therefore limits
the generalizability of our findings to young people and other population groups and regions not
included in this review. Numerous included studies did not report results in a clear, tabular form
with separate results for intervention and control groups [13,19,20,22,24,27,29,31]. In our GRADE
assessment, we downgraded the certainty of evidence due to the lack of generalizability and the poor
reporting of results. Overall, there is insufficient evidence to make general conclusions on the effects of
adjunctive antibiotics on systemic biomarkers in the treatment of periodontitis. The use of antibiotics
as an adjunct to mechanical debridement is seen to be satisfactory even though their results have
been deemed as having little difference between the antibiotic and placebo groups in the outcomes
concerning pocket depth reduction (at three months), the reduction of HbA1c, MMP-8, and CRP. The
fact that antibiotic treatment disrupts the inflammatory pathways of chronic periodontitis serves as a
justification for the adjunctive use of antibiotics with scaling and root planing (SRP) even if the clinical
benefit is minor. The adjunctive use of 400 mg or 250 mg of metronidazole plus 500 mg of amoxicillin
for 14 days provided clinically relevant benefits over SRP exclusively in the treatment of generalized
chronic periodontitis [38]. Antibiotics are not a panacea for all non-responsive situation; however,
adjunctive antibiotic use together with mechanical debridement provides effective control in chronic
periodontitis [39].
We minimized bias in the review process in a number of ways. We conducted a comprehensive
literature search of all relevant electronic database and consulted experts to identify grey or unpublished
literature and relevant information. Our search was not language-restricted and in fact, we included
one French study for which we received professional translation [35]. We also screened reference lists
of included articles to identify potentially eligible studies. At least two review authors independently
scrutinized and selected articles for inclusion in the review using pre-specified eligibility criteria.
Articles were assessed for risk of bias and data were extracted in duplicates. However, there were some
potential biases in the process of this systematic review. For instance, we did not perform separate
analyses of studies with and without comorbidities and we are therefore unable to determine if there are
differences in effects of systemic antibiotics between individuals with and without comorbidities. There
is a difference in the host response to antibiotics in a systemically healthy individual compared to an
individual with a co-morbidity during periodontal treatment [40]. We also did not compare the effects
of different antibiotics and different dosages on the outcomes. Therefore, the results from this review
will need cautious interpretation because of the broad grouping of participants and interventions.
Future updates of this systematic review will need to determine if such differences exist.
5. Conclusions
5.1. Implications for Practice
The limited available evidence shows that adjunctive administration of systemic antibiotics for a
minimum of three months may improve pocket depth clinical parameters compared to mechanical
debridement alone, among adults with chronic periodontitis. Similarly, the extended two-year duration
of adjunctive SDD with mechanical debridement may improve systemic CRP and MMPs serum levels.
5.2. Implications for Research
The included trials reported on the following outcomes: Serum/blood levels of MMPs, TIMPs,
Cytokines, CRP, IL-1β, IL-6, IL-8, CRP, HbA1c, PD, and CAL. Further rigorous large randomized
controlled trials of high quality would be beneficial to assess the effect of adjunctive antibiotics
administration on systemic biomarkers in chronic periodontitis. Most of the included trials are of
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poor methodological quality and the results were portrayed in graphic displays, making it difficult to
extract the data accurately. This limits the applicability of the result in clinical evidence-based practice.
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